Cyclosporine is a drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.
Liver transplant patients with hepatitis C virus (HCV) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination therapy. Cyclosporine also showed efficacy against Hepatitis C virus in vitro.
An international team of transplant physicians has shown that the investigational drug belatacept (LEA29Y) preserves transplanted kidney function as effectively as cyclosporine, the drug most commonly used to prevent the immune system from rejecting transplanted organs.
In an international clinical trial, a new drug that selectively blocks immune responses has proved as effective in preventing acute kidney transplant rejection as cyclosporine, the standard anti-rejection treatment.
A new study shows that a drug, called daclizumab, is effective at reducing organ rejection and risk of infection in heart transplant patients. The multi-center study by cardiologists from the United States, Sweden, Germany and Canada will be published in the June 30 issue of The New England Journal of Medicine.
A new study led by researchers at the UCLA Heart Transplant Program showed that one particular combination using tacrolimus (TAC or PrografÒ also known as FK506) had significant anti-rejection benefits for heart transplant patients over other combinations.
A new study on the incidence of liver cancer after transplant found that high levels of the immunosuppressant cyclosporine favored tumor recurrence and identified blood levels of the drug that should not be exceeded. Lower levels of cyclosporine levels did not affect rejection rates.
Data presented for the first time at the 25th Annual Meeting and Scientific Session of the International Society for Heart and Lung Transplantation (ISHLT) show that cyclosporine inhalation solution (CyIS) significantly improves long-term survival in lung-transplant patients compared to placebo.
A new study on how alcohol relapse affects survival rates after liver transplants found that it adversely affected survival rates only after 10 years. The decrease in survival rates may, however, be due to other alcohol-related diseases.
The U.S. Food and Drug Administration (FDA), today issued public health advice, patient information, and professional healthcare information on the risks and benefits of Crestor (Rosuvastatin calcium), a cholesterol-lowering drug.
Obese children who get kidney transplants tend to be younger, shorter and on dialysis longer than their leaner peers, according to a study in the February issue of the journal Pediatrics.
Patients who suffer a loss of cognitive and motor function as a result of stem cell transplantation for severe blood disorders are likely to see those functions return to previous levels after one year, according to a new study in the November 15, 2004, issue of Blood, the official journal of the American Society of Hematology.
People taking “ephedra-free” weight loss products that contain the herb Citrus aurantium, or Seville orange, may be doing more harm to their body than good, according to a new review published by Georgetown University Medical Center researchers.
Natural chemicals that assist healing may one day help transplanted adult stem cells integrate into an injured brain, helping children with cerebral palsy recover lost function, according to researchers at the Medical College of Georgia.
The difference in cost associated with using two common treatments for psoriasis over the course of one year with treatment lasting 16 weeks are small.
Kidney histology and function three years after transplantation are better in kidney-transplant patients who remain on sirolimus-based therapy following early withdrawal of cyclosporine than in patients who continue on this calcineurin inhibitor, according to a new study published in the American Journal of Transplantation.
A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.
It took a team of medical sleuths at Vanderbilt University Medical Center to get to the bottom of what was causing the 35-year-old to have abnormal blood chemistries during a post-transplant check up.
A team including MDA grantee Gordon Lynch in the Department of Physiology at the University of Melbourne in Victoria, Australia, found that a biological signaling pathway may help explain why mice with Duchenne muscular dystrophy (DMD) can regenerate their muscles much better than can humans with the same disease.